Innate Other Current Liab vs Accounts Payable Analysis

IPHA Stock  USD 1.69  0.11  6.11%   
Innate Pharma financial indicator trend analysis is infinitely more than just investigating Innate Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Innate Pharma is a good investment. Please check the relationship between Innate Pharma Other Current Liab and its Accounts Payable accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.

Other Current Liab vs Accounts Payable

Other Current Liab vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Innate Pharma Other Current Liab account and Accounts Payable. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Innate Pharma's Other Current Liab and Accounts Payable is 0.88. Overlapping area represents the amount of variation of Other Current Liab that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Innate Pharma, assuming nothing else is changed. The correlation between historical values of Innate Pharma's Other Current Liab and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Liab of Innate Pharma are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Other Current Liab i.e., Innate Pharma's Other Current Liab and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.88
Relationship DirectionPositive 
Relationship StrengthStrong

Other Current Liab

Accounts Payable

An accounting item on the balance sheet that represents Innate Pharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Innate Pharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Most indicators from Innate Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Innate Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.The current year's Selling General Administrative is expected to grow to about 14.6 M, whereas Discontinued Operations is forecasted to decline to (123.8 K).
 2021 2022 2023 2024 (projected)
Interest Income6.3M4.8M3.2M4.6M
Reconciled Depreciation4.6M45.4M5.1M4.8M

Innate Pharma fundamental ratios Correlations

0.140.790.90.870.770.81-0.85-0.330.770.920.880.410.890.630.620.40.720.050.690.950.750.950.020.670.55
0.14-0.050.020.090.28-0.350.26-0.89-0.130.040.270.540.030.640.7-0.050.240.870.650.150.40.040.640.66-0.21
0.79-0.050.810.640.350.75-0.65-0.10.880.660.550.360.710.340.290.540.52-0.030.390.780.340.84-0.110.360.69
0.90.020.810.790.650.86-0.72-0.160.660.760.780.090.690.440.40.180.46-0.060.510.850.620.870.040.470.79
0.870.090.640.790.780.59-0.78-0.220.530.830.90.310.730.580.530.080.35-0.110.650.670.730.750.00.620.43
0.770.280.350.650.780.49-0.64-0.40.380.740.850.260.620.70.71-0.040.470.040.70.660.950.620.170.760.25
0.81-0.350.750.860.590.49-0.850.150.780.780.57-0.010.780.180.140.440.58-0.320.210.840.430.86-0.240.20.67
-0.850.26-0.65-0.72-0.78-0.64-0.85-0.08-0.73-0.95-0.66-0.21-0.92-0.37-0.33-0.43-0.610.32-0.37-0.78-0.57-0.870.24-0.4-0.39
-0.33-0.89-0.1-0.16-0.22-0.40.15-0.08-0.07-0.2-0.38-0.56-0.2-0.77-0.81-0.09-0.44-0.86-0.81-0.35-0.54-0.25-0.36-0.790.06
0.77-0.130.880.660.530.380.78-0.73-0.070.720.520.50.840.280.280.80.74-0.080.310.820.330.84-0.160.310.45
0.920.040.660.760.830.740.78-0.95-0.20.720.760.380.970.560.540.430.7-0.060.570.850.70.91-0.060.60.34
0.880.270.550.780.90.850.57-0.66-0.380.520.760.410.680.660.650.130.510.010.750.750.810.70.190.710.34
0.410.540.360.090.310.26-0.01-0.21-0.560.50.380.410.510.530.590.640.620.450.550.420.310.360.380.55-0.25
0.890.030.710.690.730.620.78-0.92-0.20.840.970.680.510.510.50.650.81-0.010.520.880.590.92-0.080.540.28
0.630.640.340.440.580.70.18-0.37-0.770.280.560.660.530.510.980.120.560.470.960.590.840.540.280.990.08
0.620.70.290.40.530.710.14-0.33-0.810.280.540.650.590.50.980.150.620.530.950.60.820.520.350.980.04
0.4-0.050.540.180.08-0.040.44-0.43-0.090.80.430.130.640.650.120.150.760.080.120.55-0.020.52-0.110.12-0.01
0.720.240.520.460.350.470.58-0.61-0.440.740.70.510.620.810.560.620.760.30.560.860.510.760.00.570.15
0.050.87-0.03-0.06-0.110.04-0.320.32-0.86-0.08-0.060.010.45-0.010.470.530.080.30.480.140.210.060.360.47-0.08
0.690.650.390.510.650.70.21-0.37-0.810.310.570.750.550.520.960.950.120.560.480.630.80.570.250.970.15
0.950.150.780.850.670.660.84-0.78-0.350.820.850.750.420.880.590.60.550.860.140.630.660.960.020.610.55
0.750.40.340.620.730.950.43-0.57-0.540.330.70.810.310.590.840.82-0.020.510.210.80.660.620.210.860.24
0.950.040.840.870.750.620.86-0.87-0.250.840.910.70.360.920.540.520.520.760.060.570.960.62-0.10.560.62
0.020.64-0.110.040.00.17-0.240.24-0.36-0.16-0.060.190.38-0.080.280.35-0.110.00.360.250.020.21-0.10.3-0.18
0.670.660.360.470.620.760.2-0.4-0.790.310.60.710.550.540.990.980.120.570.470.970.610.860.560.30.08
0.55-0.210.690.790.430.250.67-0.390.060.450.340.34-0.250.280.080.04-0.010.15-0.080.150.550.240.62-0.180.08
Click cells to compare fundamentals

Innate Pharma Account Relationship Matchups

Innate Pharma fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets401.4M307.4M267.5M207.9M184.2M188.0M
Short Long Term Debt Total18.7M19.1M44.3M42.3M39.9M41.9M
Other Current Liab43.0M14.3M14.4M13.0M15.1M14.8M
Total Current Liabilities121.8M46.7M79.9M41.3M39.6M48.6M
Total Stockholder Equity217.4M156.0M107.4M54.2M51.9M81.7M
Property Plant And Equipment Net11.7M11.7M10.2M8.5M6.3M7.9M
Current Deferred Revenue48.8M12.5M12.5M6.6M5.9M5.6M
Net Debt(184.2M)(117.7M)(59.5M)(42.0M)(30.7M)(32.2M)
Retained Earnings(155.7M)(220.5M)(272.2M)(330.3M)(336.9M)(320.0M)
Accounts Payable27.9M20.7M14.7M13.7M8.6M17.0M
Cash202.9M136.8M103.8M84.2M70.6M84.5M
Non Current Assets Total163.8M134.1M129.2M68.0M36.2M55.5M
Non Currrent Assets Other16.8M30.1M30.0M14.2M19.6M20.6M
Cash And Short Term Investments218.9M151.6M119.8M101.5M92.5M106.4M
Common Stock Total Equity2.9M3.2M3.9M4.0M4.5M2.5M
Common Stock Shares Outstanding66.9M78.9M79.5M79.6M80.5M53.1M
Short Term Investments16.0M14.8M16.1M17.3M21.9M16.8M
Liabilities And Stockholders Equity401.4M307.4M267.5M207.9M184.2M188.0M
Non Current Liabilities Total62.1M104.8M80.2M112.4M92.7M57.7M
Other Stockholder Equity369.6M372.1M375.2M379.6M384.3M216.7M
Total Liab183.9M151.4M160.1M153.7M132.3M106.3M
Property Plant And Equipment Gross11.7M11.7M10.2M8.5M9.8M8.0M
Total Current Assets237.6M173.3M138.3M139.8M148.0M132.5M
Short Term Debt2.1M2.1M30.7M2.1M8.9M9.4M
Common Stock3.9M4.0M4.0M4.0M4.0M2.8M
Net Receivables13.1M10.6M846K3.1M15.2M21.7M
Accumulated Other Comprehensive Income(472K)355K456K819K495K519.8K
Inventory5.6M1.0(4.9M)(2K)(3.4M)(3.2M)
Intangible Assets97.0M46.3M44.2M42.6M416K395.2K
Other Liab45.5M87.8M66.7M72.2M65.0M74.7M
Net Tangible Assets120.4M109.7M63.2M52.6M60.5M84.3M
Long Term Debt14.1M16.9M13.5M38.9M30.6M32.1M
Capital Lease Obligations3.1M3.5M2.8M2.1M835K793.3K
Long Term Investments37.0M38.9M39.9M35.1M9.8M9.3M
Short Long Term Debt1.5M2.1M30.7M1.3M8.5M5.6M
Property Plant Equipment11.7M11.7M10.2M8.5M9.8M10.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.75)
Earnings Share
(0.44)
Revenue Per Share
0.419
Quarterly Revenue Growth
(0.69)
Return On Assets
(0.14)
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.